## WIKINGO Proyect Systematic Analysis

## Tables & Figures.

Proyecto Vikingo September 30, 2016

proyectovikingo@proyectovikingo.es

WIKINGO Project	September 30, 2016	Systematic analysis	2

(	٦,	'n	te	n	+0
ı	70	) I I	ьe	: 1 1	1.5

$\mathbf{List}$	of Tables	
1	Participant characteristics	

## List of Figures

3

Table 1: Participant characteristics

Age   65.4 (12.1)   63     Sex: Men   40 (63.5%)   63     Tumor level:   63     0-6cm   22 (34.9%)     7-11cm   28 (44.4%)     12-15cm   13 (20.6%)     Tumor stage:   63     0   2 (3.17%)     I   16 (25.4%)     II   23 (36.5%)     III   22 (34.9%)     Neoadjuvant treatment   17 (27.0%)   63     Type of resection:   63     Abdominoperineal resection   13 (20.6%)     Anterior resection   37 (58.7%)     Hartmann   13 (20.6%)     Perforation   1 (1.59%)   63     Invasion circumferential margin   4 (6.35%)   63     Mesorrecto quality:   63     Satisfactory   59 (93.7%)     Partial   3 (4.76%)     No-satisfactory   1 (1.59%)   63     Months to recidive   15.0 [5.50;19.0]   63     Metastasis   1 (1.59%)   63     Months to Metastasis   15.0 [5.50;19.0]   63     Exitus   4 (6.35%)   63     Months to exitus   15.0 [5.50;19.0]   63     Months to exitus   15.0 [5.50;19.0]			
N=63         Age       65.4 (12.1)       63         Sex: Men       40 (63.5%)       63         Tumor level:       63         0-6cm       22 (34.9%)         7-11cm       28 (44.4%)         12-15cm       13 (20.6%)         Tumor stage:       63         0       2 (3.17%)         I       16 (25.4%)         III       23 (36.5%)         III       22 (34.9%)         Neoadjuvant treatment       17 (27.0%)       63         Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)       63         No-satisfactory       1 (1.59%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63		•	N
Sex: Men       40 (63.5%)       63         Tumor level:       63         0-6cm       22 (34.9%)         7-11cm       28 (44.4%)         12-15cm       13 (20.6%)         Tumor stage:       63         0       2 (3.17%)         I       16 (25.4%)         III       23 (36.5%)         III       22 (34.9%)         Neoadjuvant treatment       17 (27.0%)       63         Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)       63         No-satisfactory       1 (1.59%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	 N	N=63	- '
Tumor level: 22 (34.9%) 7-11cm 28 (44.4%) 12-15cm 13 (20.6%) Tumor stage: 63 0 2 (3.17%) I 16 (25.4%) III 23 (36.5%) III 22 (34.9%) Neoadjuvant treatment 17 (27.0%) 63 Type of resection: 63 Abdominoperineal resection Anterior resection 37 (58.7%) Hartmann 13 (20.6%) Perforation 1 (1.59%) 63 Invasion circumferential margin 4 (6.35%) 63 Mesorrecto quality: 63 Satisfactory 59 (93.7%) Partial 3 (4.76%) No-satisfactory 1 (1.59%) 63 Months to recidive 15.0 [5.50;19.0] 63 Metastasis 1 (1.59%) 63 Months to Metastasis 15.0 [5.50;19.0] 63 Exitus 4 (6.35%) 63	Age	65.4 (12.1)	63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Sex: Men	40~(63.5%)	63
7-11cm 28 (44.4%) 12-15cm 13 (20.6%)  Tumor stage: 63 0 2 (3.17%) I 16 (25.4%) III 23 (36.5%) IIII 22 (34.9%)  Neoadjuvant treatment 17 (27.0%) 63 Type of resection: 63 Abdominoperineal resection 37 (58.7%) Hartmann 13 (20.6%) Perforation 1 (1.59%) 63 Invasion circumferential margin 4 (6.35%) 63 Mesorrecto quality: 63 Satisfactory 59 (93.7%) Partial 3 (4.76%) No-satisfactory 1 (1.59%) Recidive 3 (4.76%) 63 Months to recidive 15.0 [5.50;19.0] 63 Metastasis 1 (1.59%) 63 Months to Metastasis 15.0 [5.50;19.0] 63 Exitus 4 (6.35%) 63	Tumor level:		63
12-15cm       13 (20.6%)         Tumor stage:       63         0       2 (3.17%)         I       16 (25.4%)         III       23 (36.5%)         III       22 (34.9%)         Neoadjuvant treatment       17 (27.0%)       63         Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)       63         No-satisfactory       1 (1.59%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	$0\text{-}6\mathrm{cm}$	22 (34.9%)	
Tumor stage:       63         0       2 (3.17%)         I       16 (25.4%)         III       23 (36.5%)         IIII       22 (34.9%)         Neoadjuvant treatment       17 (27.0%)       63         Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)       63         Partial       3 (4.76%)       63         No-satisfactory       1 (1.59%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	7-11cm	28 (44.4%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$12\text{-}15\mathrm{cm}$	$13\ (20.6\%)$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tumor stage:		63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0	2(3.17%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	I	16(25.4%)	
Neoadjuvant treatment       17 (27.0%)       63         Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)         No-satisfactory       1 (1.59%)         Recidive       3 (4.76%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	II	23 (36.5%)	
Type of resection:       63         Abdominoperineal resection       13 (20.6%)         Anterior resection       37 (58.7%)         Hartmann       13 (20.6%)         Perforation       1 (1.59%)       63         Invasion circumferential margin       4 (6.35%)       63         Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)         No-satisfactory       1 (1.59%)         Recidive       3 (4.76%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	III	22 (34.9%)	
Abdominoperineal resection Anterior resection Anterior resection Hartmann 13 (20.6%) Perforation 1 (1.59%) 63 Invasion circumferential margin 4 (6.35%) 63 Mesorrecto quality: 59 (93.7%) Partial 3 (4.76%) No-satisfactory 1 (1.59%) Recidive 3 (4.76%) 63 Months to recidive 15.0 [5.50;19.0] 63 Metastasis 1 (1.59%) 63 Months to Metastasis 15.0 [5.50;19.0] 63 Exitus 4 (6.35%) 63	Neoadjuvant treatment	$17\ (27.0\%)$	63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Type of resection:		63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Abdominoperineal rese	ction $13 (20.6\%)$	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Anterior resection	37 (58.7%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Hartmann	$13\ (20.6\%)$	
Mesorrecto quality:       63         Satisfactory       59 (93.7%)         Partial       3 (4.76%)         No-satisfactory       1 (1.59%)         Recidive       3 (4.76%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	Perforation	1 (1.59%)	63
Satisfactory       59 (93.7%)         Partial       3 (4.76%)         No-satisfactory       1 (1.59%)         Recidive       3 (4.76%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	Invasion circumferential ma	rgin $4 (6.35\%)$	63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mesorrecto quality:		63
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Satisfactory	59 (93.7%)	
Recidive       3 (4.76%)       63         Months to recidive       15.0 [5.50;19.0]       63         Metastasis       1 (1.59%)       63         Months to Metastasis       15.0 [5.50;19.0]       63         Exitus       4 (6.35%)       63	Partial	3(4.76%)	
$\begin{array}{cccc} \text{Months to recidive} & 15.0 \ [5.50; 19.0] & 63 \\ \text{Metastasis} & 1 \ (1.59\%) & 63 \\ \text{Months to Metastasis} & 15.0 \ [5.50; 19.0] & 63 \\ \text{Exitus} & 4 \ (6.35\%) & 63 \\ \end{array}$	No-satisfactory	$1\ (1.59\%)$	
	Recidive	3~(4.76%)	63
Months to Metastasis $15.0 \ [5.50;19.0]$ 63 Exitus $4 \ (6.35\%)$ 63	Months to recidive	15.0 [5.50;19.0]	63
Exitus $4(6.35\%)$ 63	Metastasis	$1\ (1.59\%)$	63
	Months to Metastasis	15.0 [5.50;19.0]	63
Months to exitus 15.0 [5.50;19.0] 63	Exitus	4~(6.35%)	63
	Months to exitus	15.0 [5.50;19.0]	63